NCT04593758 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04593758
Title	To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613 (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue
Recruitment	Completed
Gender	both
Phase	Phase Ib/II
Variant Requirements	No
Sponsors	Rafael Pharmaceuticals Inc.
Indications	Ewing sarcoma clear cell sarcoma sarcoma
Therapies	CPI-613 + Hydroxychloroquine
Age Groups:	adult \| child \| senior
Covered Countries	USA

Filter rows:

Showing 1 to 8 of 8 entries

Facility	City	State	Zip	Country	Details
Atrium Health Wake Forest Baptist	Winston-Salem	North Carolina	27109	United States	Details
City of Hope	Duarte	California	91010	United States	Details
Clevland Clinic	Ohio City	Ohio	44195	United States	Details
Oregon Health and Science University	Portland	Oregon	97239	United States	Details
Seattle Children's Hospital	Seattle	Washington	98105	United States	Details
University of Kansas Medical Center	Kansas City	Kansas	66160	United States	Details
University of Michigan	Ann Arbor	Michigan	48109	United States	Details
Vanderbilt University Medical Centrer	Nashville	Tennessee	37232	United States	Details

Showing 1 to 8 of 8 entries

Filter rows:

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT04593758Clinical Trial Detail